New drugs in the management of ventricular arrhythmias.
New antiarrhythmic drugs are chiefly assigned to Class 1C and 1B: "procainamide analogues" (acecainide, lorcainide, flecainide, encainide) and propafenone for the former, and mexiletine, tocainide and aprindine for the latter. Pharmacokinetics vary widely among the different antiarrhythmic agents. These and other problems which regulate therapeutic interventions, such as patient compliance, drug interactions, efficacy/toxicity ratio, drug combinations, and drug monitoring with plasma concentrations of antiarrhythmic agents are briefly considered.
D000120:Acecainide / Q000627:therapeutic use; D000638:Amiodarone / Q000627:therapeutic use; D000813:Anilides / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use*; D001073:Aprindine / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D044482:Benzeneacetamides; D001949:Bretylium Compounds / Q000627:therapeutic use; D004347:Drug Interactions; D016700:Encainide; D005424:Flecainide; D006352:Heart Ventricles; D006801:Humans; D008012:Lidocaine / Q000031:analogs & derivatives / Q000627:therapeutic use; D008801:Mexiletine / Q000627:therapeutic use; D016293:Moricizine; D010640:Phenothiazines / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D011405:Propafenone; D011427:Propiophenones / Q000627:therapeutic use; D016677:Tocainide
D000813:Anilides; D000889:Anti-Arrhythmia Agents; D044482:Benzeneacetamides; D001949:Bretylium Compounds; D010640:Phenothiazines; D010880:Piperidines; D011427:Propiophenones; D008801:Mexiletine; D016677:Tocainide; D016293:Moricizine; D001073:Aprindine; D011405:Propafenone; D000120:Acecainide; D008012:Lidocaine; D005424:Flecainide; C015970:lorcainide; D000638:Amiodarone; D016700:Encainide